Benzinga | Aug 26, 2020 08:04AM EDT

PTC Therapeutics Receives $20M Milestone Payment From Roche Under License And Collaboration Agreement

SOUTH PLAINFIELD, N.J., Aug. 26, 2020 /PRNewswire/ --PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that the company achieved a $20 million milestone payment from Roche under its License and Collaboration Agreement. The milestone payment was triggered by the first commercial sale of Evrysdi(tm) (risdiplam) in the U.S. Evrysdi(tm) was approved by the Food and Drug Administration (FDA) on Aug. 7, for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months of age and older.